Literature DB >> 8189509

Uncoating of human rhinovirus serotype 2 from late endosomes.

E Prchla1, E Kuechler, D Blaas, R Fuchs.   

Abstract

The internalization pathway and mechanism of uncoating of human rhinovirus serotype 2 (HRV2), a minor-group human rhinovirus, were investigated. Kinetic analysis revealed a late endosomal compartment as the site of capsid modification from D to C antigenicity. The conformational change as well as the infection was prevented by the specific V-ATPase inhibitor bafilomycin A1. A requirement for ATP was also demonstrated with purified endosomes in vitro. Capsid modifications occurred at a pH of 5.5 regardless of whether the virus was entrapped in isolated endosomes or free in solution. These findings suggest that the receptor is not directly involved in the structural modification of HRV2. Viral particles found in purified endosomes of infected cells were mostly devoid of RNA. This supports the hypothesis that uncoating of HRV2 occurs in intact endosomes rather than by a mechanism involving endosomal disruption with subsequent release of the RNA into the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8189509      PMCID: PMC236876     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Internalization of intact poliovirus by HeLa cells as shown by subcellular fractionation in isoosmotic Nycodenz gradients.

Authors:  P Kronenberger; R Vrijsen; A Geerts; A Boeyé
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

2.  Stabilization of human rhinovirus serotype 2 against pH-induced conformational change by antiviral compounds.

Authors:  M Gruenberger; D Pevear; G D Diana; E Kuechler; D Blaas
Journal:  J Gen Virol       Date:  1991-02       Impact factor: 3.891

3.  Interaction of liposomes with subviral particles of poliovirus type 2 and rhinovirus type 2.

Authors:  K Lonberg-Holm; L B Gosser; E J Shimshick
Journal:  J Virol       Date:  1976-08       Impact factor: 5.103

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Protein toxins acting on intracellular targets: cellular uptake and translocation to the cytosol.

Authors:  S Olsnes; B van Deurs; K Sandvig
Journal:  Med Microbiol Immunol       Date:  1993-05       Impact factor: 3.402

6.  Recovery of structurally intact and infectious poliovirus type 1 from HeLa cells during receptor-mediated endocytosis.

Authors:  P Willingmann; H Barnert; H Zeichhardt; K O Habermehl
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

7.  Neutralization of poliovirus by cell receptors expressed in insect cells.

Authors:  G Kaplan; M S Freistadt; V R Racaniello
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

8.  Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor.

Authors:  P W Mason; B Baxt; F Brown; J Harber; A Murdin; E Wimmer
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

9.  Entry of poliovirus type 1 and Mouse Elberfeld (ME) virus into HEp-2 cells: receptor-mediated endocytosis and endosomal or lysosomal uncoating.

Authors:  H Zeichhardt; K Wetz; P Willingmann; K O Habermehl
Journal:  J Gen Virol       Date:  1985-03       Impact factor: 3.891

10.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more
  77 in total

1.  Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells.

Authors:  A Reischl; M Reithmayer; G Winsauer; R Moser; I Gösler; D Blaas
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  Poliovirus cell entry: common structural themes in viral cell entry pathways.

Authors:  James M Hogle
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

3.  Receptor priming of major group human rhinoviruses for uncoating and entry at mild low-pH environments.

Authors:  Ghasem Nurani; Birgitta Lindqvist; José M Casasnovas
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Monitoring RNA release from human rhinovirus by dynamic force microscopy.

Authors:  Ferry Kienberger; Rong Zhu; Rosita Moser; Dieter Blaas; Peter Hinterdorfer
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

6.  Nonneutralizing human rhinovirus serotype 2-specific monoclonal antibody 2G2 attaches to the region that undergoes the most dramatic changes upon release of the viral RNA.

Authors:  Elizabeth A Hewat; Dieter Blaas
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

7.  Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH.

Authors:  Abdul Ghafoor Khan; Johannes Pichler; Anke Rosemann; Dieter Blaas
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

8.  Induction of autophagy does not affect human rhinovirus type 2 production.

Authors:  Marianne Brabec-Zaruba; Ursula Berka; Dieter Blaas; Renate Fuchs
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

9.  Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis.

Authors:  Marianne Brabec; Daniela Schober; Ernst Wagner; Nora Bayer; Robert F Murphy; Dieter Blaas; Renate Fuchs
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

10.  A Novel Open and Infectious Form of Echovirus 1.

Authors:  Mira Myllynen; Artur Kazmertsuk; Varpu Marjomäki
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.